KalVista announces new sebetralstat findings

KalVista (KALV) Pharmaceuticals announced new sebetralstat findings related to time to end of progression of hereditary angioedema, HAE, attacks, and the effectiveness of treatment of attacks considered the most debilitating by patients, mucosal attacks, and attacks that have progressed in severity after a treatment delay. These data were presented at two congresses taking place concurrently: the 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference, EAC, in Palm Beach, Florida, from May 29-June 1, 2025. Data on sebetralstat include: Time to end of attack progression in KONFIDENT-S: median 19.8 minutes; Results from the open-label extension aligned closely with the pivotal phase 3 trial, KONFIDENT, reinforcing the rapid effect of sebetralstat after absorption; Patients were able to self-administer sebetralstat quickly; The median time to beginning of symptom relief was 1.3 hours for both abdominal and laryngeal attacks; Of attacks reaching symptom relief within 12 hours, 96% did so before or without the need for an additional sebetralstat administration ; Sebetralstat was well-tolerated, even in laryngeal attacks; Sebetralstat was used to treat 76 attacks that had progressed to severe or very severe after a median of 2.16 hours from attack onset; The median time to beginning of symptom relief for these attacks was 1.36 hours, with reduction in attack severity and substantial reduction of symptom burden in a median of 1.77 hours and 9.15 hours, respectively